ACTRN12622000377730招募中1 期
Phase I open-label clinical trial of allogeneic SARS-CoV-2-specific T cells for patients at risk of severe COVID-19
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Aged 18 years or above
- •2. Active SARS-CoV-2 infection, confirmed by rapid antigen test or polymerase chain reaction
- •3. Immunosuppression due to: transplantation, receipt of immunosuppressive therapy, or receipt of chemotherapy to treat malignancy
- •4. Availability of a suitable batch of Investigational Product
排除标准
- •1.Psychiatric condition that may compromise the ability to participate in this trial
- •2.Women who are pregnant, lactating or women of child-bearing potential who are unwilling to use adequate contraception
- •3.Any other medical condition that, in the view of the Investigator, would prohibit participation
- •4.Participants who have undergone prior allogeneic HSCT and have active acute graft-versus-host disease (GvHD) grade greater than or equal to 2 or chronic GvHD requiring greater than or equal to 0.5 mg/kg prednisolone
研究者
相似试验
招募中
1 期
Virus-specific T cell therapy for transplant recipientsACTRN12621000323820QIMR Berghofer Medical Research Institute40
终止
1 期
A clinical trial of adoptive T-cell immunotherapy for patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.Metastatic nasopharyngeal carcinomaCancer - Head and neckACTRN12613000866707QIMR Berghofer Medical Research Institute18
进行中（未招募）
1 期
Phase I clinical trial on the use of fresh, allogeneic, second-generation CD19-CAR T cells for treatment of children and young adult with relapsed/refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/refractory B-cell Acute Lymphoblastic LeukemiaCTIS2023-508420-36-00Ospedale Pediatrico Bambino Gesu'24
已完成
不适用
Phase I clinical trial of newly developed antigen peptide vaccine for advanced esophageal cancerAdvanced esophageal squamous cell carcinoma patietns treated with standart therapy includingn surgery, chemotherapy and radiotherapy, and all these treatments were failed.JPRN-UMIN000004662Chiba University5
已完成
不适用
Allogeneic NK Cell (SMT-NK) in Combination With Pembrolizumab in Advanced Biliary Tract CancerKCT0004324SMT Bio40